An oral SARS-CoV-2 M <sup>pro</sup> inhibitor clinical candidate for the treatment of COVID-19

R. Owen, Dafydd; Allerton, Charlotte; S. Anderson, Annaliesa; Aschenbrenner, Lisa; Avery, Melissa; Berritt, Simon; Boras, Britton; D. Cardin, Rhonda; Carlo, Anthony; J. Coffman, Karen; Dantonio, Alyssa; Di, Li; Eng, Heather; Ann Ferre, Rose; Gajiwala, K.S.; Gibson, Scott; Greasley, S.E.; L. Hurst, Brett; P. Kadar, Eugene; S. Kalgutkar, Amit; C. Lee, Jack; Lee, Jisun; Liu, Wei; W. Mason, Stephen; Noell, Stephen; J. Novak, Jonathan; Scott Obach, R.; Ogilvie, Kevin; C. Patel, Nandini; Pettersson, Martin; K. Rai, Devendra; R. Reese, Matthew; F. Sammons, M.; G. Sathish, Jean; Shankar Prasad Singh, Ravi; M. Steppan, Claire; Stewart, Al; B. Tuttle, Jamison; W. Updyke, Lawrence; R. Verhoest, Patrick; Wei, Liuqing; Yang, Qingyi; Zhu, Yuao

doi:10.1126/science.abl4784

Public

An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19

Published in Science • Nov 2, 2021

Authors:

Dafydd R. Owen

Charlotte Allerton

Annaliesa S. Anderson

Abstract

Path to another drug against COVID-19 The rapid development of vaccines has been crucial in battling the ongoing COVID-19 pandemic. However, access challenges remain, breakthrough infections occur, and emerging variants present increased risk. Developing antiviral therapeutics is therefore a high pr...

Subject

Potency

Outbreak

Coronavirus disease 2019 (COVID-19)

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!